Clinical Trial Update: Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating targeted alpha therapy with Actinium-225 PSMA-I&T for metastatic castration-resistant prostate cancer, sponsored by Fusion Pharmaceut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 225Ac-PSMA-I&T (Actinium-225 PSMA-I&T)

Snippet

Sponsor: Fusion Pharmaceuticals Inc. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING